Skip to main content

Engineering of Mycoplasma pneumoniae as a broad-spectrum animal vaccine

Objective

Mycoplasmas are the smallest cell wall less, free-living microorganisms. The lack of a cell wall makes them resistant to many of the common antibiotics. Every year, infections caused by Mycoplasmas in poultry, cows, and pigs, result in multimillion euros losses in USA and Europe. Currently, there are vaccines against M hyopneumoniae in pigs and M gallisepticum and M synoviae in poultry. However, there is no vaccination against many Mycoplasma species infecting pets, humans and farm animals (ie M bovis cow infection). Mycoplasma species in many cases are difficult to grown in axenic culture and those that grow need a complex media with animal serum. In large scale production of Mycoplasma species for vaccination aside from the high cost of animal serum, more important is the high irreproducibility in the production process and the possible contamination with animal viruses. All this together highlights what European industry needs:i) a defined cheap reproducible medium that is animal serum free and ii) an universal Mycoplasma chassis that could be used in a pipeline to vaccinate against Mycoplasma species, as well as any pathogen. M pneumoniae is an ideal starting point for designing such a vaccine chassis. It has a small genome (860 kb) and it is probably the organism with the most comprehensive systems biology data acquired so far. By genome comparison, metabolic modeling and rationally engineering its genome, we will create a vaccine chassis that will be introduced into an industrial pipeline. The process will be guided by the second world largest industry on animal vaccination (MSD), as well as a SME specialized on peptide display and screening. This will ensure the exploitation and commercialization of our work contributing to maintain Europe privileged position in this field. Our ultimate goal is to meet the needs of the livestock industry,taking care of ethical issues, foreseeable risks, and prepare effective dissemination and training material for the public.

Field of science

  • /natural sciences/biological sciences/microbiology/virology
  • /agricultural sciences/animal and dairy science/pets
  • /natural sciences/biological sciences/genetics and heredity/genome
  • /medical and health sciences/basic medicine/pharmacology and pharmacy/pharmaceutical drug/vaccines

Call for proposal

H2020-LEIT-BIO-2014-1
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

FUNDACIO CENTRE DE REGULACIO GENOMICA
Address
Carrer Doctor Aiguader 88
08003 Barcelona
Spain
Activity type
Research Organisations
EU contribution
€ 2 128 507

Participants (7)

INTERVET INTERNATIONAL BV
Netherlands
EU contribution
€ 1 476 250
Address
Wim De Korverstraat 35
5831 AN Boxmeer
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT
France
EU contribution
€ 850 300
Address
147 Rue De L'universite
75007 Paris Cedex 07
Activity type
Research Organisations
WAGENINGEN UNIVERSITY
Netherlands
EU contribution
€ 860 008
Address
Droevendaalsesteeg 4
6708 PB Wageningen
Activity type
Higher or Secondary Education Establishments
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE
United Kingdom
EU contribution
€ 699 977
Address
South Kensington Campus Exhibition Road
SW7 2AZ London
Activity type
Higher or Secondary Education Establishments
ATG:BIOSYNTHETICS GMBH
Germany
EU contribution
€ 897 493
Address
Weberstrasse 40
79249 Merzhausen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
KOBENHAVNS UNIVERSITET
Denmark
EU contribution
€ 591 750
Address
Norregade 10
1165 Kobenhavn
Activity type
Higher or Secondary Education Establishments
BIOFACTION KG
Austria
EU contribution
€ 552 392
Address
Kundmanngasse 39/12
1030 Wien
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)